Influenza A virus (IAV) infection provokes an antiviral response involving the expression of type I and III interferons (IFN) and
Influenza A viruses (IAVs) are prototypic members of the Orthomyxoviridae family, featuring a segmented RNA genome composed of eight single-stranded RNAs that have negative polarity (1). IAVs circulate in the human population, causing periodic epidemic outbreaks and occasional pandemic waves of respiratory disease (2). Moreover, there is a large natural IAV host reservoir in wild aquatic birds, such as ducks and geese, in which the viruses cause mainly mild or no apparent symptoms. IAV strains are usually well adapted to their particular host species, which is reflected not only in the existence of stable virus lineages but also in polymorphic amino acid positions in viral proteins distinctively found in human or avian strains (3).IAVs target the epithelial cell layers lining the human respiratory tract, in which they are subject to immune control in infected cells, mediated by the antiviral type I interferon (IFN) response (4). Many of the key events and factors driving the IFN response have been identified and involve initial recognition of the viral genomic 5=-triphosphorylated RNA by the intracellular RNA helicase RIG-I, which governs a signaling module culminating in the activation of transcription factors, such as IRF-3 and NF-B, thereby inducing the transcription of type I IFN genes (5, 6). Type I IFNs comprise 14 subtypes of IFN-␣ and one IFN- that are secreted from virus-infected cells and exert antiviral effects against many virus families, including IAV (4, 7). Type I IFNs secreted by